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HIV/AIDS	
Rachel	Muir,	BSN,	RN	
Introduc0on	
Human	Immunodeficiency	Virus	(HIV)	is	a	disease	in	which	the	virus	a8acks	and	
depletes	the	CD4+	T	cells	leading	to	a	weakened	immune	system	in	which	a	paBent	can	
no	longer	fight	pathogens.	This	weakening	of	the	paBent’s	immune	system	makes	them	
more	suscepBble	to	opportunisBc	infecBons	and	malignancies	(Coffin	&	Swanstrom,	
2017).	In	the	iniBal	acute	HIV	infecBon	period	the	paBent	usually	does	not	show	
symptoms	but	is	highly	infecBous	which	can	allow	for	transmission	unknowingly	
(Center	for	Disease	Control	and	PrevenBon,	2017).		HIV	can	eventually	progress	to	AIDS	
without	treatment.		
Admission	to	the	hospital	can	expose	this	paBent	to	many	opportunisBc	pathogens	and	
complicate	treatment	plan.		
In	Columbus,	Ohio,	at	Grant	Medical	Center	there	is	a	need	for	be8er	understanding	of	
HIV	and	the	impact	it	can	potenBally	have	on	paBents	who	are	acutely	ill	in	the	criBcal	
care	seUng	which	is	why	this	topic	was	chosen.	
Underlying	Pathophysiology	
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HIV	is	a	virus	which	is	a	member	of	the	lenBvirus	genus,	part	of	the	retroviridae	family	
(Moss,	2013).	The	characterisBcs	of	this	family	of	viruses	are	long	latency	periods	and	
progressive	infecBon	allowing	the	virus	to	invade	the	hosts	immune	response	(Moss,	
2013).	On	the	surface	of	the	HIV	are	two	anBgens,	glycoproteins	120	and	41	(gp120	
and	gp	41)	which	allow	the	virus	to	bind	with	the	target	cell	using	CXCR4	and	CCR5	as	
co-receptors.	CCR5	is	expressed	on	memory	cells	where	CXCR4	is	expressed	on	
memory	and	naïve	CD4	T	cells	(Swanstrom	&	Coffin,	2013).	HIV	starts	with	the	
infecBon	of	a	single	CD4	T	cell.	Once	in	the	cell,	RNA	is	released	in	the	cytoplasm	of	
the	cell.	Using	the	host’s	nucleoBdes,	HIV	enzyme	reverse	transcriptase	transforms	
the	viral	RNA	into	single-stranded	DNA.	As	this	occurs,	errors	are	made	due	to	poor	
“proofreading”	and	single	stranded	DNA	is	reverse-transcribed	and	synthesized	as	
double-stranded	DNA.	The	double	stranded	DNA	is	then	carried	to	the	nucleus	and	
inserts	it	into	the	hosts	chromosome.	(Moss,	2013).		HIV	conBnues	to	replicate	in	CD4	
T	cells	and	as	a	new	viron	is	formed	cell	death	occurs	to	the	host	allowing	the	virus	to	
be	released	to	infect	other	CD4	cells	(Swanstrom	&	Coffin,	2013).	As	the	virus	
replicates	there	is	a	significant	decrease	in	CD4	T	cells	over	Bme	leading	to	
immunodeficiency;	leaving	the	host	suscepBble	to	infecBons	and	malignancies	(Moss,	
2013).		
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• 	Transmission	of	the	HIV	virus	occurs	from	and	infected	
person	by	blood,	semen	and	vaginal	fluids	through	means	
such	as	needlesBcks,	intravenous	drug	use,	sexual	
intercourse,	blood	products	or	mother-to-child.	
• Up	to	80%	of	transmission	in	adults	is	through	sexual	
intercourse	(Moss,	2013).	Early	diagnosis	and	treatment	is	
key	to	prevent	further	transmission	and	control	of	the	
disease	progression.	Most	HIV	viruses	can	be	detected	
within	25-30	days	(Moss,	2013)	
As	more	research	is	done	and	innovaBons	conBnue,	
the	hope	is	to	eventually	eradicate	the	HIV	virus.	At	
this	Bme	vaccine	trials	have	not	been	effecBve.	Yet,	
as	we	understand	more	about	the	global	geneBc	
variaBons	and	their	specific	pathogenic	potenBal	
reducing	new	infecBons	and	finding	a	cure	is	
becoming	more	of	a	reality.	These	breakthroughs	
allowed	The	United	States,	in	2010,	to	develop	a	
plan	to	address	AIDS	by	decreasing	these	new	
infecBons,	increasing	access	to	care	and	improving	
the	outcomes	to	those	with	HIV	(Kla8,	Chomont,	
Douek	&	Deeks,	2013).		
Implica0ons	for	Nursing	Care	
• EducaBon	to	those	who	are	at	high	risk	for	
contracBng	this	disease	is	important.	HIV	is	more	
common	among	ethnic/racial	minoriBes,	
homosexual	and	bisexual	men,	and	intravenous	
drug	users	(Moss,	2013).		
• To	decrease	transmission	among	high	risk	groups	
educaBon	such	as	safe	sex	pracBce	using	condoms,	
using	clean	needles	for	intravenous	drug	use	as	well	
as	importance	of	tesBng	are	all	crucial.		
• Under	the	Affordable	Care	Act,	HIV	screening	is	
covered	without	co-pay	to	those	who	have	health	
insurance	and	many	other	resources	are	available	
for	those	who	are	not	covered	by	health	insurance.	
• 	Once	a	paBent	has	contracted	HIV,	early	start	of	
anBretroviral	therapy	(ART)	is	important.	There	are	
many	federal	and	state	resource	available	for	those	
who	are	not	covered	by	insurance	to	help	pay	for	
ART	therapy	(HIV.gov,	2017).		.	
Significance	of	Pathophysiology	
Conclusion	
HIV	Diagnosis	&	Treatment	
Three	types	of	tests	are	available	to	detect	and	diagnose	HIV.	They	are	anBbody	tests,	
combinaBon	or	fourth-generaBon	tests,	and	nucleic	acid	tests	(NATs).	
An0body	detec0on	tests:	ELISA	is	a	test	in	which	HIV	anBgens	are	used	to	detect	
anBbodies	in	the	paBent’s	blood	serum.	The	CDC	recommends	confirmaBon	of	the	
posiBve	result	of	the	ELISA	test	using	Western	blot	test.	The	Western	blot	test	is	able	to	
idenBfy	anBbodies	of	a	specific	molecular	weight,	eliminaBng	false	posiBve	results	
(Moss,	2013).	
Combina0on	or	fourth-genera0on	tests:	These	tests	are	looking	for	both	anBgens	and	
anBbodies		
which	can	be	detected	2	to	6	weeks	amer	infecBon	(Center	for	Disease	Control	and	
PrevenBon,	2017)	
Nucleic	acid	tests:	This	test	is	the	fastest,	it	is	able	to	detect	the	virus	in	the	blood	amer	
7	to	28	days.		
This	test	is	typically	not	used	due	to	the	high	cost	(CDC,	2017).	
Treatment:	Once	a	diagnosis	has	been	made,	early	treatment	is	imperaBve.	Although	
there	is	currently	no	cure	for	HIV,	the	use	of	highly	acBve	anBretroviral	therapy	(HAART)	
has	decreased	morbidity	and	mortality	to	those	diagnosed	with	HIV.	These	drugs	
decrease	the	viral	load	which	slows	the	progression	of	the	disease	as	well	as	decreasing	
the	risk	of	transmission.	(Moss,	2013).	The	progression	of	anBretroviral	therapy	has	
make	this	once	deadly	disease	into	a	manageable	chronic	disease	(Sweet,	AlBce,	Cohen	
&	Vandewalle,	2016).	
Signs	&	Symptoms	
The	HIV	infecBon	occurs	in	four	stages:	
Stage	1-	During	the	primary	infecBon,	which	lasts	for	a	few	weeks,	the	person	may	or	
may	not	have	symptoms.	Symptoms	present	are	usually	flu-like	such	as	fever,	
headache,	muscle	ache,	rash	and	joint	pain	(HIV.gov,	2017).	During	this	stage	there	is	
a	significant	amount	of	HIV	circulaBng	and	the	immune	system	is	responding	by	
generaBng	anBbodies,	a	process	called	seroconversion,	allowing	the	paBents	to	test	
posiBve	when	tests	are	conducted	for	anBbodies	(Moss,	2013)	
Stage	2-	During	the	clinically	asymptomaBc	stage	most	symptoms	are	absent	with	the	
excepBon	of	swollen	glands.	Although	the	paBent	may	not	have	symptoms,	the	
individual	is	sBll	infecBous	(Moss,	2013).	This	stage	can	last	on	average	ten	years	
without	anBretroviral	therapy,	and	for	much	longer	in	those	receiving	anBretroviral	
therapy	(HIV.gov,	2017).			
Stage	3-	Following	the	asymptomaBc	stage,	HIV	becomes	symptomaBc	when	the	CD4	
lymphocyte	count	drops	below	200	cells/uL.	As	the	immune	system	is	weakened	due	
to	damage	of	Bssues	and	lymph	nodes,	viral	mutaBon	and	further	destrucBon	of	T	
cells,	the	person	becomes	more	suscepBble	to	opportunisBc	infecBons	and	
malignancies	(Moss,	2013).	Symptoms	at	this	Bme	can	include:	rapid	weight	loss,	
night	sweats,	diarrhea,	pneumonia,	red,	brown,	pink	or	purple	blotches	on	skin	and	
memory	loss	or	other	neurologic	disorders	(HIV.gov,	2017).	As	the	person	progresses	
to	AIDS,	they	are	more	likely	to	be	suscepBble	to	more	severe	infecBons	and	cancers.	
Examples	are	Hodgkin	disease,	squamous	cell	carcinoma	and	severe	
lymphadenopathy	(Moss,	2013).	Retrieved	from	h8p://sahiv.yolasite.com	
Retrieved	from	h8ps://www.boundless.com/microbiology/textbooks/
boundless-microbiology-textbook/viruses-9/-and-host-cell-
entry-647-918/	
